Aptevo Therapeutics Inc. (APVO) stock
APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.45−0.02 (-3.25%)
Close on Nov 18, 2026Market cap $803.68KP/E –Yield –
Aptevo Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Aptevo Therapeutics's revenue for the twelve months ending Dec 31, 2022 was $3.11M, down 74.7% year over year. For fiscal 2022 it was $3.11M, down 74.7% from the year before. The highest annual figure on record is $33.60M in fiscal 2015.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $3.11M | -74.7% |
| FY2021 | Dec 31, 2021 | $12.29M | +185.3% |
| FY2020 | Dec 31, 2020 | $4.31M | -86.7% |
| FY2019 | Dec 31, 2019 | $32.42M | +40.6% |
| FY2018 | Dec 31, 2018 | $23.07M | +57.4% |
| FY2017 | Dec 31, 2017 | $14.66M | +46.8% |
| FY2016 | Dec 31, 2016 | $9.99M | -70.3% |
| FY2015 | Dec 31, 2015 | $33.60M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2022 | Dec 31, 2022 | $0 | -100.0% |
| Q3 FY2022 | Sep 30, 2022 | $0 | -100.0% |
| Q2 FY2022 | Jun 30, 2022 | $0 | -100.0% |
| Q1 FY2022 | Mar 31, 2022 | $3.11M | +28.6% |
| Q4 FY2021 | Dec 31, 2021 | $3.67M | +54.4% |
| Q3 FY2021 | Sep 30, 2021 | $3.10M | +111.6% |
| Q2 FY2021 | Jun 30, 2021 | $3.11M | +557.5% |
| Q1 FY2021 | Mar 31, 2021 | $2.42M | -73.2% |
| Q4 FY2020 | Dec 31, 2020 | $2.37M | -73.7% |
| Q3 FY2020 | Sep 30, 2020 | $1.46M | -80.1% |
| Q2 FY2020 | Jun 30, 2020 | $473.00K | -93.3% |
| Q4 FY2019 | Dec 31, 2019 | $9.03M | +42.3% |
| Q3 FY2019 | Sep 30, 2019 | $9.01M | +54.7% |
| Q2 FY2019 | Jun 30, 2019 | $7.36M | +7.8% |
| Q1 FY2019 | Mar 31, 2019 | $7.02M | +72.5% |
| Q4 FY2018 | Dec 31, 2018 | $6.35M | +125.2% |
| Q3 FY2018 | Sep 30, 2018 | $5.82M | -5.6% |
| Q2 FY2018 | Jun 30, 2018 | $6.83M | +93.6% |
| Q1 FY2018 | Mar 31, 2018 | $4.07M | +90.1% |
| Q4 FY2017 | Dec 31, 2017 | $2.82M | -67.9% |
| Q3 FY2017 | Sep 30, 2017 | $6.17M | +119.2% |
| Q2 FY2017 | Jun 30, 2017 | $3.53M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.14M | – |
| Q4 FY2016 | Dec 31, 2016 | $8.77M | – |
| Q3 FY2016 | Sep 30, 2016 | $2.82M | – |
See a number that looks wrong?